Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Background Alzheimer's disease (AD) is a complex multifactorial neurodegenerative
disorder and the most common form of dementia. AD is highly heritable, with heritability …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Cell-based therapies are being developed for various neurodegenerative diseases that
affect the central nervous system (CNS). Concomitantly, the roles of individual cell types in …

Apolipoprotein E (APOE) is a strong genetic risk factor for late-onset Alzheimer's disease
(LOAD). APOE4 increases and APOE2 decreases risk relative to APOE3. In the P301S …

Presenilin mutations that alter γ-secretase activity cause familial Alzheimer's disease (AD),
whereas ApoE4, an apolipoprotein for cholesterol transport, predisposes to sporadic AD …

Cells can die as a consequence of being phagocytosed by other cells—a form of cell death
that has been called phagotrophy, cell cannibalism, programmed cell removal and primary …

Genetic association studies have demonstrated the critical involvement of the microglial
immune response in Alzheimer's disease (AD) pathogenesis. Phospholipase C-gamma-2 …

Neurodegenerative disorders, including Alzheimer's disease, are associated with
microgliosis. Microglia have long been considered to have detrimental roles in Alzheimer's …

Cholesterol homeostasis is impaired in Alzheimer's disease; however, attempts to modulate
brain cholesterol biology have not translated into tangible clinical benefits for patients to …